{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer%27s+Disease+Psychosis&page=2",
    "query": {
      "condition": "Alzheimer's Disease Psychosis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer%27s+Disease+Psychosis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T15:20:52.921Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03325556",
      "title": "Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dementia-related Psychosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pimavanserin 34 mg",
          "type": "DRUG"
        },
        {
          "name": "Pimavanserin 20 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ACADIA Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 392,
      "start_date": "2017-09-27",
      "completion_date": "2019-10-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-21",
      "last_synced_at": "2026-06-10T15:20:52.921Z",
      "location_count": 27,
      "location_summary": "Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03325556"
    },
    {
      "nct_id": "NCT06540833",
      "title": "A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psychosis Associated With Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "ITI-1284",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intra-Cellular Therapies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 370,
      "start_date": "2024-08-15",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-06-10T15:20:52.921Z",
      "location_count": 27,
      "location_summary": "Anaheim, California • Costa Mesa, California • Lafayette, California + 19 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06540833"
    },
    {
      "nct_id": "NCT05847192",
      "title": "Tau Networks in Psychotic Alzheimer's Disease",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer Disease",
        "Alzheimer Disease With Delusions",
        "Alzheimer Disease With Psychosis"
      ],
      "interventions": [
        {
          "name": "[18F]-PI2620 PET scan",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "65 Years to 85 Years"
      },
      "enrollment_count": 91,
      "start_date": "2023-04-13",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-06-10T15:20:52.921Z",
      "location_count": 1,
      "location_summary": "Manhasset, New York",
      "locations": [
        {
          "city": "Manhasset",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05847192"
    },
    {
      "nct_id": "NCT00036114",
      "title": "Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "55 Years to 95 Years"
      },
      "enrollment_count": null,
      "start_date": "2000-03",
      "completion_date": "2003-08",
      "has_results": false,
      "last_update_posted_date": "2013-11-11",
      "last_synced_at": "2026-06-10T15:20:52.921Z",
      "location_count": 41,
      "location_summary": "Tuscaloosa, Alabama • Scottsdale, Arizona • Cerritos, California + 38 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00036114"
    },
    {
      "nct_id": "NCT01862640",
      "title": "A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation Associated With",
        "Alzheimer's Disease",
        "Alzheimer's Type",
        "Mental Disorder",
        "Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "Brexpiprazole, OPC-34712",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 433,
      "start_date": "2013-07-11",
      "completion_date": "2017-03-15",
      "has_results": true,
      "last_update_posted_date": "2020-12-31",
      "last_synced_at": "2026-06-10T15:20:52.921Z",
      "location_count": 37,
      "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01862640"
    },
    {
      "nct_id": "NCT02392468",
      "title": "Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Placebo matching BI 409306 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching BI 409306 50 mg",
          "type": "DRUG"
        },
        {
          "name": "BI 409306 25 mg",
          "type": "DRUG"
        },
        {
          "name": "BI 409306 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2015-04-15",
      "completion_date": "2017-08-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-19",
      "last_synced_at": "2026-06-10T15:20:52.921Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Eatontown, New Jersey • Austin, Texas",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Eatontown",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02392468"
    },
    {
      "nct_id": "NCT06947941",
      "title": "A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Psychosis"
      ],
      "interventions": [
        {
          "name": "KarXT",
          "type": "DRUG"
        },
        {
          "name": "KarX-EC",
          "type": "DRUG"
        },
        {
          "name": "KarXT + KarX-EC Arm Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 325,
      "start_date": "2026-03-25",
      "completion_date": "2028-03-20",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-06-10T15:20:52.921Z",
      "location_count": 6,
      "location_summary": "Gilbert, Arizona • Chino, California • Naples, Florida + 2 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06947941"
    },
    {
      "nct_id": "NCT06194799",
      "title": "ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease Psychosis"
      ],
      "interventions": [
        {
          "name": "ACP-204",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ACADIA Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "55 Years to 95 Years"
      },
      "enrollment_count": 752,
      "start_date": "2024-04-23",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-06-10T15:20:52.921Z",
      "location_count": 19,
      "location_summary": "Costa Mesa, California • Fresno, California • Hialeah, Florida + 6 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06194799"
    },
    {
      "nct_id": "NCT05309577",
      "title": "Self-Care for Dementia Caregivers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aging",
        "Mental Disorder",
        "Eating, Healthy",
        "Physical Inactivity",
        "Prodromal Symptoms",
        "Sleep",
        "Alzheimer Disease",
        "Dementia",
        "Circadian Rhythm Disorders"
      ],
      "interventions": [
        {
          "name": "Behavioral Self-Monitoring + Motivational Interviewing",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "50 Years to 99 Years"
      },
      "enrollment_count": 21,
      "start_date": "2023-03-07",
      "completion_date": "2025-03-10",
      "has_results": true,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-06-10T15:20:52.921Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05309577"
    },
    {
      "nct_id": "NCT05245903",
      "title": "Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer Disease",
        "Dementia Alzheimers",
        "Dementia",
        "Cognitive Impairment",
        "Mild Cognitive Impairment",
        "Neurodegenerative Diseases",
        "Neurocognitive Disorders",
        "Neurocognitive Dysfunction",
        "Cognitive Dysfunction",
        "Mental Disorder"
      ],
      "interventions": [
        {
          "name": "Emerald Device Monitoring",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mclean Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-05-31",
      "completion_date": "2026-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-06-10T15:20:52.921Z",
      "location_count": 1,
      "location_summary": "Belmont, Massachusetts",
      "locations": [
        {
          "city": "Belmont",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05245903"
    }
  ]
}